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Abstract
In 2018, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) concluded that whey basic
protein isolate obtained by ion exchange chromatography from skimmed cow’s milk is safe for human
consumption under the proposed conditions of use as infant and follow on formula, meal replacement
beverages, foods for special medical purposes and food supplements. Following a request from the
European Commission, the EFSA NDA Panel was asked to deliver a scientiﬁc opinion on whey basic protein
isolate for extended uses in foods for special medical purposes and food supplements for infants as a
novel food (NF) pursuant to Regulation (EU) 2015/2283. The applicant seeks to extend the conditions of
use to infant (powder 30 mg/100 g and reconstituted 3.9 mg/100 mL) and follow on formulae (powdered
30 mg/100 g and reconstituted 4.2 mg/100 mL) as foods for special medical purposes as well as in food
supplements for infants (25 mg/day). The Panel considers that the proposed extended uses would not
increase the potential intake of the NF compared to that assessed in its 2018 opinion. The Panel concludes
that whey basic protein isolate is safe at the extended uses and use levels.
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Summary
The European Commission implementing regulation (EU) 2018/1632 authorised, in accordance with
Regulation (EC) 2283/2015 and following the European Food Safety Authority (EFSA)’s Opinion, the
placing on the market of whey protein isolates as a novel food (NF) ingredient to be used in infant and
follow on formulae, total diet replacements, foods for special medical purposes and food supplements.
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and
Food Allergens (NDA) was asked to deliver a scientiﬁc opinion on whey basic protein isolate for
extended uses in foods for special medical purposes and food supplements for infants as a NF
pursuant to Regulation (EU) 2015/2283. The assessment of the safety of this NF, which follows the
methodology set out in the EFSA Guidance on the preparation and presentation of an application for
authorisation of a novel food Regulation (EU) 2015/2283 and in the European Commission
implementing Regulation (EU) 2017/2469, is based on the data supplied in the application.
In 2018, the EFSA NDA Panel concluded that whey basic protein isolates obtained by ion exchange
chromatography from skimmed cow’s milk was safe for human consumption under the proposed
conditions of use. In the application subject of that assessment, the applicant intended to target the
NF to infants (infant and follow-on formulae), the general adult population (meal replacement
beverages) and the general population above 1 year of age (foods for special medical purposes
(FSMP) and food supplements). The Panel considered margins of exposure (MOE) of 81, 72 and 154 to
be sufﬁcient for infants, toddlers and the adult population, respectively.
The applicant intends to market the use of the NF in FSMP and food supplements as alternative
sources to its use in infant and follow on formula. The Panel notes that the use levels for the FSMP
formulae for infants proposed by the applicant are identical to the use levels of the NF for infant and
follow on formulae assessed by EFSA in 2018. Considering a combined intake of 5 mg/kg body weight
(bw) per day from food supplements plus 20 mg/kg bw per day from either FSMP formula or from the
authorised use in infant and follow-on formula, the MOE would result to 80 which is considered
sufﬁcient by the Panel, in line with the conclusions of its Opinion from 2018.
The Panel concludes that the NF, whey basic protein isolate, is safe under the new proposed
conditions of use.
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1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
On 10 October 2018, the company Armor Proteines S.A.S. submitted a request to the European
Commission in accordance with Article 10 of Regulation (EU) No 2015/22831 to update the entry for
Bovine Milk Basic Whey Protein Isolate in the Union list of authorised novel foods entry to extent its
uses in food supplements and foods for special medical purposes for infants up to 12 months of age.
In accordance with Article 10(3) of Regulation (EU) 2015/2283, the European Commission asks the
European Food Safety Authority to provide a scientiﬁc opinion by carrying out the assessment for the
extension of use of the novel food Bovine Milk Basic Whey Protein Isolate.
2. Data and methodologies
2.1. Data
The assessment of the safety of whey protein isolates at the new proposed uses and use levels is
based on the data provided by the applicant and the scientiﬁc opinion on the safety of whey basic
protein isolates (EFSA NDA Panel, 2018).
2.2. Methodologies
The assessment follows the methodology set out in the EFSA guidance on novel food (NF)
applications and the principles described in the relevant existing guidance documents from the EFSA
Scientiﬁc Committee. The legal provisions for the assessment are laid down in Article 11 of Regulation
(EU) 2015/2283 and in Article 7 of the Commission Implementing Regulation (EU) 2017/2469.
This assessment concerns only risk that might be associated with consumption of the NF under the
proposed conditions of use, and is not an assessment of the efﬁcacy of whey basic protein isolate with
regard to any claimed beneﬁt.
3. Assessment
On 27 June 2018, the EFSA NDA Panel concluded that whey basic protein isolates obtained by ion
exchange chromatography of skimmed cow’s milk was safe for human consumption under the
proposed conditions of use (EFSA NDA Panel, 2018). In the application subject of that assessment, the
applicant intended to target the NF to infants (infant and follow-on formulae), the general adult
population (meal replacement beverages) and the general population above 1 year of age (foods for
special medical purposes (FSMP) and food supplements). Taking into account the source, the
production process and the nature of the NF and the no observed adverse effect level (NOAEL) of
2,000 mg/kg body weight (bw) per day, the highest dose tested in a subchronic rat study, the
Panel considered margins of exposure (MOE) of 81, 72 and 154 to be sufﬁcient for infants, toddlers
and the adult population, respectively.
In 2018, European Commission Implementing Regulation (EU) 2018/1632 granted marketing
authorisation of the NF for its uses in infant formula, follow-on formula, total diet replacement foods
for weight control, FSMP and food supplements, the latter two uses restricted to children aged 1–
3 years, children and adolescents from 3 to 18 years of age and adults.
In this application, the applicant requests the additional uses of the NF for food supplements
targeted to infants (up to 12 months of age) and FSMP as an alternative use to the use of the NF in
infant and follow on formula (Table 1). The applicant proposes to label the food supplements ‘Product
should not be consumed in conjunction with infant formula (standard or FSMP) containing basic whey
protein isolate’.
1 Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods, amending Regulation (EU) No 1169/2011
of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the European Parliament and of the
Council and Commission Regulation (EC) No 1852/2001 (OJ L 327, 11.12.2015, p. 1).
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3.1. Anticipated intake/extent of use of the NF (extension of use)
Considering the default body weight of 5 kg proposed by the EFSA Scientiﬁc Committee (2012) for
the dietary exposure assessments for infants, a daily intake of 25 mg of the NF from its uses as a food
supplement, corresponds to 5 mg/kg bw per day.
The Panel notes that the use levels for the FSMP formulae for infants proposed by the applicant are
identical to the use levels of the NF for infant and follow on formulae assessed by EFSA (EFSA NDA
Panel, 2018). The estimated 95th percentile of the daily intake of the NF from FSMP therefore
corresponds to the 95th percentile intake estimate for infants considered by EFSA in its Opinion from
2018 (20 mg/kg bw per day). The Panel notes that this high percentile intake proposed by the applicant
and considered by the Panel in 2018 is based on the summary statistics from the EFSA Comprehensive
European Food Consumption Database from 2011 and represents an overestimate of the exposure.
Considering the default value of 260 mL/kg bw for high consumption of infant formula by infants
below 16 weeks of age as suggested by the EFSA Scientiﬁc Committee (2017) and taking into account
the intended use level of 3.9 mg/100 mL, the resulting exposure to the NF would amount to 10 mg/kg
bw per day.
The applicant intends to market the use of the NF in FSMP and food supplements as alternative
sources to its use in infant and follow on formula. However, the Panel notes that a combined
unintended intake of 5 mg/kg bw per day from food supplements and 20 mg/kg bw per day from
either infant and follow on formulae or from FSMP formulae would not exceed the intake level which
were considered safe by the EFSA Opinion of 2018 (EFSA NDA Panel, 2018).
4. Discussion
Considering a combined intake of 5 mg/kg bw per day from food supplements plus 20 mg/kg bw
per day from either FSMP formulae or from the authorised use in infant and follow-on formula, the
MOE would result to 80 which is considered sufﬁcient by the Panel, in line with its conclusions of its
Opinion from 2018 (EFSA NDA Panel, 2018).
5. Conclusions
The Panel concludes that the NF, whey basic protein isolates, is safe under the new proposed
conditions of use.
Documentation provided to EFSA
1) Letter from the European Commission to the European Food Safety Authority with the
request for a scientiﬁc opinion on the safety of Basic whey protein isolate as a novel food
ingredient. Ref. Ares(2019)406975 - 24/01/2019, dated 24 January 2019.
Table 1: Authorised and proposed uses of the NF for infants (children < 12 months of age)
Uses Max use level
Authorised use
Infant formulae
Follow-on formulae
30 mg/100 g(a)
3.9 mg/100 mL(b)
30 mg/100 g(a)
4.2 mg/100 mL(b)
Proposed extended uses
Food Supplements as deﬁned in Directive 2002/46/EC for infants (< 12 months of age) 25 mg/day
FSMP as deﬁned in Regulation (EU) No 609/2013:
FSMP for infants (Infant formulae)
FSMP for infants (Follow on formulae)
30 mg/100 g(a)
3.9 mg/100 mL(b)
30 mg/100 g(a)
4.2 mg/100 mL(b)
FSMP: foods for special medical purposes.
(a): Powder.
(b): Reconstituted.
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2) On 24 January 2019, EFSA received a valid application from the European Commission on
whey basic protein isolate as NF, which was submitted by Armor Proteines S.A.S., and the
scientiﬁc evaluation procedure started.
3) During its meeting on 14 March 2019, the NDA Panel, having evaluated the data, adopted a
scientiﬁc opinion on the safety of whey basic protein isolate as a NF pursuant to Regulation
(EU) 2015/2283.
References
EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), Turck D, Bresson J-L, Burlingame B,
Dean T, Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI, Mangelsdorf I, McArdle HJ, Naska A, Neuh€auser-
Berthold M, Nowicka G, Pentieva K, Sanz Y, Siani A, Sj€odin A, Stern M, Tome D, Vinceti M, Willatts P, Engel
K-H, Marchelli R, P€oting A, Poulsen M, Schlatter JR, Amundsen M and van Loveren H, 2018. Scientiﬁc Opinion
on the safety of Whey basic protein isolates as a novel food pursuant to Regulation (EU) 2015/2283. EFSA
Journal 2018;16(7):5360, 18 pp. https://doi.org/10.2903/j.efsa.2018.5360
EFSA Scientiﬁc Committee, 2012. Guidance on selected default values to be used by the EFSA Scientiﬁc
Committee, Scientiﬁc Panels and Units in the absence of actual measured data. EFSA Journal 2012;10(3):2579,
32 pp. https://doi.org/10.2903/j.efsa.2012.2579. Available online: www.efsa.europa.eu
EFSA Scientiﬁc Committee, Hardy A, Benford D, Halldorsson T, Jeger MJ, Knutsen HK, More S, Naegeli H, Noteborn H,
Ockleford C, Ricci A, Rychen G, Schlatter JR, Silano V, Solecki R, Turck D, Bresson J-L, Dusemund B, Gundert-
Remy U, Kersting M, Lambre C, Penninks A, Tritscher A, Waalkens-Berendsen I, Woutersen R, Arcella D, Court
Marques D, Dorne J-L, Kass GEN and Mortensen A, 2017. Guidance on the risk assessment of substances present
in food intended for infants below 16 weeks of age. EFSA Journal 2017;15(5):4849, 58 pp. https://doi.org/10.
2903/j.efsa.2017.4849
Abbreviations
bw body weight
FSMP Foods for special medical purposes
NDA EFSA Panel on Nutrition, Novel Foods and Food Allergens
NF novel food
NOAEL no observed adverse effect level
MOE margin of exposure
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